Cascadian Therapeutics announces approval of nonproprietary name "tucatinib"
Cascadian Therapeutics announced the United States Adopted Names Council and the International Nonproprietary Names Expert Group have approved the nonproprietary name "tucatinib" for ONT-380, the Company's lead product candidate for treatment of advanced, metastatic HER2+ breast cancer. August 31, 2016